Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer

Prostate cancer is the second cause of cancer-related deaths in men worldwide, and new agents for curing the disease are still needed. In this study, we theoretically and experimentally demonstrated that valeric acid (VA) was a HDAC inhibitor, and anti-cancer efficacy of VA in prostate cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Rui, Yang, Hongxing, Li, Ya, Ling, Changquan, Lu, Lingeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522682/
https://www.ncbi.nlm.nih.gov/pubmed/36175803
http://dx.doi.org/10.1007/s12032-022-01814-9
_version_ 1784800111380922368
author Han, Rui
Yang, Hongxing
Li, Ya
Ling, Changquan
Lu, Lingeng
author_facet Han, Rui
Yang, Hongxing
Li, Ya
Ling, Changquan
Lu, Lingeng
author_sort Han, Rui
collection PubMed
description Prostate cancer is the second cause of cancer-related deaths in men worldwide, and new agents for curing the disease are still needed. In this study, we theoretically and experimentally demonstrated that valeric acid (VA) was a HDAC inhibitor, and anti-cancer efficacy of VA in prostate cancer cells was also observed using either 2D or 3D culture systems. VA was cytotoxic for prostate cancer cells but low toxic to normal cells. VA significantly inhibited E2F1/E2F3 expression but increased CASP3 activity. In vivo mouse models further showed its anti-cancer activity and potential property of chemosensitizer with promoting apoptosis. The findings suggest that VA acts as a HDAC3 inhibitor with anti-cancer effect on prostate cancer by regulating E2F1/E2F3/CASP3 axis.
format Online
Article
Text
id pubmed-9522682
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-95226822022-10-01 Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer Han, Rui Yang, Hongxing Li, Ya Ling, Changquan Lu, Lingeng Med Oncol Original Paper Prostate cancer is the second cause of cancer-related deaths in men worldwide, and new agents for curing the disease are still needed. In this study, we theoretically and experimentally demonstrated that valeric acid (VA) was a HDAC inhibitor, and anti-cancer efficacy of VA in prostate cancer cells was also observed using either 2D or 3D culture systems. VA was cytotoxic for prostate cancer cells but low toxic to normal cells. VA significantly inhibited E2F1/E2F3 expression but increased CASP3 activity. In vivo mouse models further showed its anti-cancer activity and potential property of chemosensitizer with promoting apoptosis. The findings suggest that VA acts as a HDAC3 inhibitor with anti-cancer effect on prostate cancer by regulating E2F1/E2F3/CASP3 axis. Springer US 2022-09-29 2022 /pmc/articles/PMC9522682/ /pubmed/36175803 http://dx.doi.org/10.1007/s12032-022-01814-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Han, Rui
Yang, Hongxing
Li, Ya
Ling, Changquan
Lu, Lingeng
Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
title Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
title_full Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
title_fullStr Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
title_full_unstemmed Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
title_short Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
title_sort valeric acid acts as a novel hdac3 inhibitor against prostate cancer
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522682/
https://www.ncbi.nlm.nih.gov/pubmed/36175803
http://dx.doi.org/10.1007/s12032-022-01814-9
work_keys_str_mv AT hanrui valericacidactsasanovelhdac3inhibitoragainstprostatecancer
AT yanghongxing valericacidactsasanovelhdac3inhibitoragainstprostatecancer
AT liya valericacidactsasanovelhdac3inhibitoragainstprostatecancer
AT lingchangquan valericacidactsasanovelhdac3inhibitoragainstprostatecancer
AT lulingeng valericacidactsasanovelhdac3inhibitoragainstprostatecancer

Ejemplares similares